EU to study potential vaccine for Lyme disease: companies / Photo: BERTRAND GUAY - AFP
-
Billionaire Ambani's Jio soars in market debut after India's biggest IPO
-
Three killed by storm in southern India
-
AI chip giant SK hynix posts seven-fold surge in quarterly operating profit
-
Two hundred 'Cruise for life' passengers stranded in Cambodia
-
S.African activists push back on data centre rush
-
Billionaire Ambani's Jio jumps 21% in market debut after record India IPO
-
Billionaire Ambani's Jio to debut after record India IPO
-
Sri Lanka's Tamil farmers fight to reclaim land after civil war
-
UK set for cautious budget as borrowing costs climb
-
'They don't care about us': Trump food aid cuts leave Americans struggling and angry
-
US Fed expected to hold rates steady ahead of key midterm elections
-
Palestinian activist Khalil returns to Columbia after US detention
-
AI chip giant SK hynix says quarterly operating profit soars 630%
-
Youths testify about 'despair' in unprecedented Canadian climate trial
-
Charles tackles thorny legacy of slavery on Caribbean trip
-
Storied Paris department store seeks bankruptcy protection
-
UN nuclear watchdog chief urges Iran to grant access
-
Boeing shares tumble after it releases cautious growth forecast
-
Boeing releases cautious growth plan as shares fall sharply
-
Boeing reports smaller loss as it aims for stable output growth
-
Tech firms gain on Anthropic IPO optimism; HSBC slumps in London
-
Dangote, Nigeria's oil tycoon rewriting Africa's story
EU to study potential vaccine for Lyme disease: companies
EU officials have agreed to study an experimental vaccine against Lyme disease, the world's most common tick-borne illness, its developers said Friday.
Pfizer and the French-Swiss firm Valneva say trials have shown a 70 percent efficacy rate in people aged five and above for a disease that currently has no approved vaccine.
Despite a disappointing trial result earlier this year, the two firms said the European Medicines Agency had accepted its application for approval of its treatment, formally called PF-07307405.
While rarely fatal, Lyme disease can cause rashes and flu-like symptoms among people who are bitten by an infected tick, and in some cases neurological problems.
"We believe vaccination has the potential to provide an important new layer of protection against this debilitating disease," Pfizer's chief vaccines officer, Annaliesa Anderson, said in a joint statement.
Research in 2022 estimated that more than 14 percent of the global population has had the disease, warning that transmission rates could increase as climate change brings longer, drier summers.
Shares in Valneva surged nearly 16 percent on the news in early trading on the Paris stock exchange Friday.
The EMA's acceptance "represents a major milestone, especially considering that more than 200 million people live in Lyme disease risk areas in Europe," Valneva's chief executive Thomas Lingelbach said in the statement.
A.Zimmermann--CPN
